Tarsons Products Ltd
Tarsons Products Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Domestic market expected to deliver good, stable growth over the next 2-3 years due to strong market position and product portfolio expansion. FY'27 PAT expected to remain moderate due to higher depreciation and interest costs from new capex.
From Tarsons Products Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Domestic market expected to deliver good, stable growth over the next 2-3 years due to strong market position and product portfolio expansion.
- International market growth projected to be significantly higher percentage-wise compared to domestic, driven by lower base and large opportunities.
- Growth may be uneven given geopolitical and economic factors but strong years anticipated with new contract wins and ODM business expansion.
- Bioprocessing containers and cell culture production lines ramping up; pilots underway, with scaling starting from year 2, reaching stability around years 4-5.
- Raw material price volatility is a challenge; price hikes are gradual and cautious to maintain competitiveness.
2 more points from Tarsons Products Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Tarsons Products Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major new capex planned for FY'27 or FY'28; focus is on completing pending CWIP and ongoing capex.
- FY'27 capex mainly maintenance and commercially viable projects, approximately INR 20 crores.
- The large-scale capex program from past 4 years is entering final phase; most facilities commissioned and operational.
- Balance commissioning and trial runs in progress; full commissioning expected in first half of current financial year (FY'27).
- No additional strategic investments announced currently.
- Focus for next 2-3 years is on capacity ramp-up, scaling operations, revenue growth, and deleveraging rather than new capex.
2 more points from Tarsons Products Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tarsons Products Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- No explicit mention of a specific current or expected order book value or pending orders in the transcript.
- Aryan Sehgal mentions ongoing efforts to get products validated and become vendors globally, indicating continuous order inflow.
- Ramp-up of new product lines like bioprocess containers and cell culture is underway with pilot production starting; scale-up expected from FY'28 onward.
- The company’s exports and domestic market growth strategy involves targeting new customers and contracts, but no quantified order backlog disclosed.
2 more points from Tarsons Products Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Tarsons Products Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹121 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tarsons Products Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Q-Line Biotech Ltd (Q4 FY26)
Shift towards more manufacturing with gross margins of 60-65% for reagents supporting profitability improvement (Page 7, 6). Key concall takeaways from Q-Line…
- Vasa Denticity Ltd (Q4 FY26)
The company has a debt line of ₹15 crore available from financial partners. Key concall takeaways from Vasa Denticity Ltd's Q4 FY26 earnings call — and how it…
- QMS Medical Allied Services Ltd (Q4 FY26)
INR 13 crores in FY26 to INR 18-20 crores in FY27. Key concall takeaways from QMS Medical's Q4 FY26 earnings call — and how it ranks against sector peers.
- Laxmi Dental Ltd (Q4 FY26)
Export revenue (currently 33-34%) has tremendous potential alongside domestic; focus will be opportunity-driven (Page 11). Key concall takeaways from Laxmi…
Arthneeti Pro · Annual
Tarsons Products Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tarsons Products Ltd Q4 FY26 results?
Domestic market expected to deliver good, stable growth over the next 2-3 years due to strong market position and product portfolio expansion. FY'27 PAT expected to remain moderate due to higher depreciation and interest costs from new capex.
What is Tarsons Products Ltd share price analysis?
Tarsons Products Ltd currently shows a neutral. The stock trades at a P/E of 161.9 with a market cap of ₹1,917 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products Ltd planning capital expenditure?
No major new capex planned for FY'27 or FY'28; focus is on completing pending CWIP and ongoing capex.
Keep Tarsons Products Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.